Panniculitis with Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma

American Journal of Dermatopathology

Volumn 37, Issue 8, 2015, Pages e96-e99

  Ramani, Nisha S ^a   Curry, Jonathan L ^a,b   Kapil, Jyoti ^a   Rapini, Ronald P ^b   Tetzlaff, Michael T ^a   Prieto, Victor G ^a,b   Torres Cabala, Carlos A ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

BRAF inhibitors; melanoma; necrotizing granuloma; panniculitis

Indexed keywords

DABRAFENIB; DOXYCYCLINE; INTERLEUKIN 2; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEMALE; GRANULOMATOUS SKIN DISEASE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; METASTATIC MELANOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NECROTIZING GRANULOMATA; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE IMAGING; PANNICULITIS; PRIORITY JOURNAL; PUNCH BIOPSY; SUBCUTANEOUS NODULE; TREATMENT DURATION; CHEMICALLY INDUCED; GENETICS; GRANULOMA; MELANOMA; NECROSIS; PATHOLOGY; SECONDARY; SKIN; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; GRANULOMA; HUMANS; IMIDAZOLES; MELANOMA; MIDDLE AGED; NECROSIS; OXIMES; PANNICULITIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN; SKIN NEOPLASMS;

EID: 84938560280     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0000000000000230     Document Type: Article

References (16)

1. Besaratinia A, Pfeifer GP. Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. Hum Mutat. 2008;29:983-991.
2. Heinzerling L, Baiter M, Kuhnapfel S, et al. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer. 2013;109:2833-2841.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
4. Ravnan MC, Matalka MS. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther. 2012;34:1474-1486.
5. Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67:1265-1272.
6. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24:1691-1697.
7. Huang V, Hepper D, Anadkat M, et al. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012;148:628-633.
8. Choy B, Chou S, Anforth R, et al. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36:493-497.
9. Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B, et al. Vemurafenib-associated neutrophilic panniculitis: an emergent adverse effect of variable severity. Dermatol Online J. 2013;19:16.
10. Monfort JB, Pages C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res. 2012;22:399-401.
11. Zimmer L, Livingstone E, Hillen U, et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148:357-361.
12. Sinha R, Edmonds K, Newton-Bishop J, et al. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. J Clin Oncol. 2013;31:e320-e321.
13. Kim GH, Levy A, Compoginis G. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol. 2013;40:667-669.
14. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366: 707-714.
15. Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006;354:2623-2624.
16. Prendiville J, Thiessen P, Mallory SB. Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colonystimulating factor (G-CSF) therapy. Pediatr Dermatol. 2001;18:417-421